PubMed · 1996 · 39 citations · 1 references
MedicineNeurologyPharmacologyClinical PharmacologyMovement DisordersPharmacovigilanceAdverse Drug Event ReportingDrug-induced Movement DisordersMovement Disorder PharmacotherapyParkinson DiseaseParkinsonian DisordersPharmacoepidemiologyAcute Adverse EventsAdverse Drug EventsDrug-induced Parkinsonism ManagementParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyPrevalence RatePrevalence Rate AnalysisSerious Adverse Events
We analyze 402 drug-adverse events consisting of movement disorders or aggravation of parkinsonisms, submitted to Sistema Español de Farmacovigilancia until 1994. Our aim is to know patient characteristics and the drugs related with these submissions. Most of them (64) belong to calcium-entry blocker group (31%) and benzamides (27%). Case age intervals more frequent were 11-30 and 60-80 years-old and the events affect predominantly females. The percentage of serious adverse events were near 80%. We think that drug-related parkinsonisms have high prevalence rate and that the role of calcium-entry blockers in these events should be considered at the moment to prescribe groups.
1
Sulfation factor: studies of its removal from plasma and metabolic fate in cartilage.
Daughaday Wh, Heins Jn, Lalit M. Srivastava et al. · PubMed · 1968 · 45 citations